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Abstract  1 
Objective: This study aimed to explore the incidence and prevalence of OA in the UK in 2017 2 
and their trends from 1997-2017 using a large nationally representative primary care database. 3 
Design: The UK Clinical Practice Research Datalink (CPRD) comprising data on nearly 17.5 4 
million patients was used for the study. The incidence and prevalence of general practitioner 5 
diagnosed OA over a 20 years period (1997-2017) were estimated and age-sex and length of 6 
data contribution standardized using the 2017 CPRD population structure. Cohort effects were 7 
examined through Age-period-cohort analysis. 8 
Results: During 1997-2017, there were 494,716 incident OA cases aged >20 years. The 9 
standardised incidence of any OA in 2017 was 6.8 per 1000 person-years (95% CI 6.7 to 6.9) 10 
and prevalence was 10.7% (95% CI 10.7 to 10.8%). Both incidence and prevalence were higher 11 
in women than men. The incidence of any-OA decreased gradually in the past 20 years at an 12 
annual rate of -1.6% (95%CI -2.0 to -1.1%), and the reduction speeded up for people born after 13 
1960. The prevalence of any-OA increased gradually at an annual rate of 1.4% (95% CI 1.3 to 14 
1.6%). Although the prevalence was highest in Scotland and Northern Ireland, incidence was 15 
highest in the East Midlands. Both incidence and prevalence reported highest in the knee 16 
followed by hip, wrist/hand and ankle/foot. 17 
Conclusion:  In the UK approximately one in 10 adults have symptomatic clinically diagnosed 18 
OA, the knee being the commonest. While prevalence has increased and become static after 19 
2008, incidence is slowly declining. Further research is required to understand these changes.   20 
 21 
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Introduction 24 
Osteoarthritis (OA) is one of the commonest long-term conditions, causing significant 25 
impairment of physical function. It can affect several joints which may further compound 26 
functional impairment and participation restriction. In the absence of any cure, the burden of 27 
OA is increasing globally with an estimated 28% of the older population (>60 years) having 28 
OA.1 The 2017 Global Burden of Disease (GBD) report ranked hip and knee OA as the 11th 29 
highest contributor to global disability and the 23rd highest cause of disability adjusted life 30 
years (DALYs).2 Increasing life expectancy and the ageing population are expected to make 31 
OA the fourth leading cause of disability by  2020 3 and a significant increase in DALYs has 32 
already been noted from 2007 to 2017.2 33 
Whilst DALYs provide useful data on disease burden, accurate information on changing 34 
incidence and prevalence of a disease provides an alternative picture to help guide effective 35 
preventive and management planning. To date, very few studies have examined trends of OA 36 
incidence and prevalence using national representative cohort data. The lack of such 37 
information creates challenges in reliable estimation of the burden of OA. Worldwide, the 38 
estimated incidence of OA has varied from a low of 14.6 per 1000 person-years in Canada 4 to 39 
a high of 40.5 per 1000 person-years in the UK.5 Only three countries have reported increasing 40 
trends of the incidence of OA, whereas none has published prevalence trend data.  In Sweden, 41 
age-standardized hospitalization rates due to hip and knee OA increased from 1998 to 2014 6 42 
and in Canada crude incidence rates increased during 2000 to 2008 from 11.8 to 14.2 per 1000 43 
person-years in men, and from 15.7 to 18.5 person-years in women.4 However, one UK study 44 
using the Clinical Practice Research Datalink (CPRD) reported no change in trends of 45 
incidence of physician-diagnosed OA (1992-2013).5 Seven years of consultation data till 2010 46 
reveals nearly 8.75 million people in the UK had visited any health facility for treatment of 47 
OA, and by 2035, 8.3 million people in the UK aged 45 years or over could have symptomatic 48 
knee OA.7 49 
Primary care is the usual first point of contact for someone with symptomatic OA. The UK 50 
CPRD is a primary care database that represents the community burden in better ways than 51 
hospital (secondary care) records and allows evaluation of the trends of incidence and 52 
prevalence over time. However, these estimates depend on the nature of consultation, the 53 
coding system and other individual factors. While the incidence measures the aetiological 54 
impact of OA, the prevalence measures the disease burden to inform health resource 55 
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requirements. Although there have been some incidence and prevalence studies from the UK 56 
5,8,9, they have given inconsistent results through use of different definitions and sampling 57 
methods. Therefore, the recent trend and natural history of OA in UK primary care remains 58 
largely unknown. 59 
This study aimed to explore both the incidence and prevalence of OA (overall and joint 60 
specific) in the UK during the period 2017 and their trends during 1997-2017 using a large 61 
nationally representative primary care database. 62 
Methods  63 
This was a descriptive study using longitudinal primary care database of the UK. 64 
Source population 65 
The CPRD is a large database of general practice electronic medical records that is 66 
generalisable to the wider UK population. As of 31st December 2017, the CPRD contained data 67 
on 17,480,766 individuals from 736 general practices. Recording of ailment is mandatory for 68 
every visit and there is no limit on the number of diagnoses entered. The database contains 69 
information on symptoms, diagnoses, prescriptions, referrals, tests, immunisations, life style 70 
factors, information on medical staff, health promotion activities, management and quality 71 
outcome framework indicators.10 Substantial research has been undertaken to examine the 72 
validity and completeness of the CPRD and has provided satisfactory results.11 More details 73 
about the database can be found at https://cprd.com/primary-care. This study was approved by 74 
the independent scientific advisory committee for CPRD research (protocol reference: 19_030 75 
R). No further ethical permissions were required for the analyses of these anonymized patient 76 
level data. 77 
Study population 78 
 CPRD data available for patients registered from 1st January 1997 until 31st December 2017 79 
was used for the study. Inclusion criteria were  individual records with: (i) people aged 20 years 80 
or more during each study year of 1997 to 2017; (ii) active registration for at least 12 months 81 
with the up-to-standard practice prior to the study start date (determined by CPRD database 82 
standards); and (iii) data quality flagged as ‘acceptable’ in the database.  83 
 84 
 85 
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Case definition of OA 86 
Incident OA was defined as the first diagnosis of OA within each study year. Prevalent OA 87 
was defined as having an OA diagnosis by 1st July of each study year. We used Read codes: a 88 
medical coding system of clinical terms used by national health services (NHS), UK.12 The 89 
available Read code list (www.keele.ac.uk/mrr ) to identify people with a GP diagnosed OA 90 
was adapted according to our inclusion and exclusion criteria. We used the exact list but 91 
excluded two OAs (acromio-clavicular and sterno-clavicular joints), because of the possible 92 
low accuracy of diagnosis at these joints and the expected incidence is very low. The codes 93 
obtained from the given website was previously matched with ICD-10 codes (Musculoskeletal 94 
disorder chapter).9 Even though not all OA joint codes have been validated, a recently 95 
published article shows the positive predictive value (PPV) for Read codes for hip OA in people 96 
aged 60 and over was nearly 80% and suitable for research purposes.13 The Read codes for OA 97 
(N05…) used in the study was further screened by two independent GPs before the use. 98 
(Appendix 1)  99 
The index date was defined as the date of the first diagnosis of OA recorded in the database. 100 
Patients meeting the following criteria were excluded from both incidence and prevalence 101 
estimation: (i) any recording of joint diseases (rheumatoid arthritis, psoriatic arthritis, systemic 102 
lupus erythematosus, ankylosing spondylitis, septic arthritis, spondyloarthropathy or crystal 103 
disease and human parvovirus B19 infection) before or within three years after the index date; 104 
(ii) any record of specific non-OA diagnosis (soft-tissue disorders, other bone/cartilage 105 
diseases) at the same joint in the 12 months before or after the recorded OA consultation; and 106 
(iii) any history of joint injury within 1 year prior to the index date. In the absence of a recording 107 
of OA during the study year, any recording of joint replacement was taken as a proxy measure 108 
of OA. 109 
Estimation of incidence and prevalence 110 
The annual incidence rate for OA was defined as the number of incident (new) OA cases 111 
between 1st January and 31st December, divided by the number of person-years at risk for each 112 
calendar year from 1997 to 2017.  Person-years of follow-up were calculated for eligible people 113 
at risk (i.e. no previous diagnosis of OA) from the latest of 1st January to the earliest date of 114 
transfer-out, last data collection, incident diagnosis of OA, death or 31st December of the study 115 
year. The annual prevalence of OA was calculated by dividing the number of people ever 116 
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diagnosed with OA at 1st July of each calendar year, by the total number of eligible people in 117 
the population at the same time point of the calendar year.   118 
Statistical analysis 119 
The incidence and prevalence for each year from 1997 to 2017 were standardised according to 120 
age (5 years band), sex and length of data contribution (observation period) using the CPRD 121 
population structure in the year 2017 as reference. This method of adjustment for the 122 
observation period has been used previously.14 The length of data contribution of each patient 123 
was defined as the period from the up to standard date for participants to 1st July of each 124 
calendar year for prevalence and 1st January of each calendar year for incidence. Up to standard 125 
date is always later the registration date. the length of data contribution was then categorised 126 
in four groups 0-3 years, 4-6 years, 7-9 years and >=10 years. Standardization by length of data 127 
contribution was done because higher estimates were observed for longer lengths of data 128 
contribution. (Supplementary fig S1) For 1997, no data contribution was seen for >=10 years. 129 
(Supplementary Fig S1 and S2) Because, even though the first registration date with the 130 
database was traced back before 1987, the up to standard practice data started recording in 131 
1988, which is acceptable as a quality data, as per CPRD. For sex specific estimation, only age 132 
and length of data contribution standardisation was done. Age-sex standardized incidence and 133 
prevalence of OA in 2014 were calculated for all 13 regions of the UK and plotted using  134 
choropleth maps in QGIS software (V.3, Open source).15 The prevalence and incidence for the 135 
UK region after 2014 could not be estimated adequately because of lack of information from 136 
the East Midlands region from 2015 onwards. 137 
Age-sex and length of data standardized trends (overall and sex specific) of the incidence and 138 
prevalence of OA were calculated for any-OA, joint specific and unspecified OA for 1998-139 
2017. Unspecified OA cases are coded as ‘unspecified’ in the database without any mentioning 140 
of the site involved. We computed the incidence and prevalence across each age group for both 141 
sexes only for the year 2017. The 95% confidence interval (CIs) were derived based on the 142 
assumption of a Poisson distribution for the observed cases. The trends were tested using 143 
Joinpoint regression analysis16  with Joinpoint software (Version 4.6.0.0).17 Bayesian 144 
Information Criterion (BIC) was used to identify the ‘join points’, which describes the 145 
significant change across the trend line and best-fit data series. Using BIC, a maximum of three 146 
joinpoints were selected. Annual percentage changes for each segment and average annual 147 
percentage changes (AAPC) for the entire study period were calculated at the significance level 148 
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of 0.05 using the empirical model.18 Additional, trend analysis of joint pain incidence was done 149 
using the same database. Details are provided in Supplementary Fig S8.  150 
Both incidence and prevalence trends were modelled as a function of age at diagnosis, period 151 
(year of diagnosis) and birth (year of birth) cohort. To assess the cohort effect, age-period-152 
cohort (A-P-C) analysis was undertaken.19 For visual clarity incidence and prevalence were 153 
aggregated in five-year age groups for period and birth cohort graphs.  The A-P-C analysis was 154 
performed in R using the package ‘Epi’ and ‘APC’.20–22 Statistical analyses were performed 155 
using STATA ( SE v 15, STATA corp, Texas) and R(V 5.2, R software, Austria).23,24 156 
Results  157 
Incidence and prevalence 158 
In 2017, the total person-years of follow up for any-OA was 1,495,497 with 10,147 incident 159 
OA cases, and the incidence was 6.8 per 1000 person-years (95% CI 6.7 to 6.9 per 1000 person-160 
years). The incidence was higher in women (8.1; 95% CI 7.9 to 8.3) than in men (5.5; 95% CI 161 
5.3 to 5.7 per 1000 person-years). The age-specific incidence in 2017 shows that OA was very 162 
rare in people less than 30 years of age. The incidence was 0.08 per 1000 person-years in both 163 
sexes which increased gradually with age and peaked at 75-79 years at 27 per 1000 person-164 
years (95% CI 23.5 to 29.8 per 1000 person-years) in women and 18 per 1000 person-years 165 
(95% CI 15.4 to 20.6 per 1000 person-years) in men. (Fig 1 A) 166 
Of 1,690,618 eligible individuals in 2017, 181,464 had a recorded diagnosis of any-OA. The 167 
prevalence in 2017 was 10.8% (95% CI: 10.7 to 10.9%) which was higher in women (12.8%; 168 
95% CI 12.8 to 12.9%) than men (8.6%; 95% CI 8.5 to 8.7%) across all age groups. The 169 
prevalence increased sharply at age 40-44 years in women and 45-49 years in men. In both men 170 
and women, the increasing trend continued until age group of >80 years, reaching the peak of 171 
47% for women and 35% for men. (Fig 1 B) 172 
The joint-specific OA incidence (per 1000 person-years) in 2017 was highest for knee (2.3; 173 
95% CI 2.2 to 2.4) followed by hip (1.1; 95% CI 1.1 to 1.2), wrist and hand (0.65; 95% CI 0.6 174 
to 0.7) and ankle and foot (0.2; 95% CI 0.2 to 0.2). The incidence of unspecified OA was 5.2 175 
per 1000 person-years (95% CI 5.1 to 5.3). All joint-specific incidence rates were higher in 176 
women than in men. The detailed distribution across age in both men and women is given in 177 
Supplementary Fig S3. In descending  order, the overall prevalence according to joint site in 178 
2017 was ; knee (2.9%, 95% CI 2.7 to 2.9%), hip (1.5%, 95%CI 1.4 to 1.5%), wrist or hand 179 
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(0.5%, 95%CI 0.5 to 0.5%) and ankle or foot (0.3%, 95% CI 0.3 to 0.3%). The prevalence of 180 
unspecified OA was 7.6% (95%CI 7.5 to 7.6%). The distribution of joint site and unspecified 181 
OA across the sex is provided in Supplementary Fig S4. 182 
Temporal trends of incidence and prevalence  183 
The incidence (both crude and standardised) of any OA decreased over time during the study 184 
period, changing from 9.5 per 1000 person-years (95% CI 9.4 to 9.7 per 1000 person-years) to 185 
6.8 per 1000 person-years (95% CI 6.7 to 6.9 per 1000 person-years). (Table 1) Similar trends 186 
were seen in both women and men (Fig 2 A). The incidence of OA in men declined from 8.0 187 
per 1000 person-years (95% CI 7.8 to 8.3 per 1000 person-years) in 1997 to 5.5 per 1000 188 
person-years (95% CI 5.3 to 5.7 per 1000 person-years) in 2017, whereas in women the 189 
incidence reduced from 11.5 per 1000 person-years (95% CI 11.2 to 11.7 per 1000 person-190 
years) to 8.1 per 1000 person-years (95%CI 7.9 to 8.3 per 1000 person-years). Joinpoint 191 
analysis identified two points of changes in overall trend at 2002 and 2005. The AAPC was -192 
1.6% (95% CI -2.0 to -1.1%), indicating a slight decline in the incidence since 1998. Women 193 
(-1.9.1%; 95% CI -2.2 to -1.6%) had a higher decline in rates compared to men (-1.5%; -1.1 to 194 
-1.9%).  No change in trend was observed for ankle and foot and wrist and hand sites. Whereas, 195 
unspecified OA trend was on decline, while OA at knee and hip showed slightly increasing 196 
trend . Details of joint specific incidence trends are given in Supplementary Fig S5 and sex 197 
wise distribution is given in supplementary table S1. 198 
In contrast, prevalence increased from 1998 to 2017. (Table 1) The age and length of data 199 
standardised rates were found to rise in both men and women across the years. The overall 200 
prevalence of people with any OA in 2017 was found to increase to 10.7% from 8.2% in 1998, 201 
1.3 times increase in prevalence over this period. (Fig 2 B) The average annual percentage 202 
change was 1.4% (95% CI 1.3 to 1.6%) for any OA, whereas among women it was a 1.6% 203 
(95% CI 1.4 to 1.8%) and in men a 1.3% (95% CI 1.1 – 1.4%) change each year. The prevalence 204 
of OA in joint-specific OA in 2017 also increased from 1998 except for ankle and foot. Details 205 
are given in Supplementary Fig S6 and sex wise distribution is given in supplementary table 206 
S2. The additional analysis on trends of incidence of joint pain recorded in the CPRD shows a 207 
sudden increase in the trends after 2003. (Supplementary Fig S8) 208 
 209 
 210 
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Geographic distribution 211 
In 2014, the East Midlands and the North East had the highest incidence rates of OA of 12.6 212 
per 1000 person-years and 11.7 per 1000 person-years respectively. Lowest incidence rates 213 
were seen in Northern Ireland and South East England. (Fig 3A) The prevalence of any OA 214 
varied from one region to another within the UK. In 2014 the highest age and sex standardised 215 
prevalence were in Scotland, West Midlands and Northern Ireland ranging from 7%-9%. The 216 
prevalence ranged from 3%-5% in the Southern region. (Fig 3B)  217 
Cohort effects 218 
The incidence was found to decline according to the birth cohorts.  For people in the same age 219 
group, those born later were less likely to have OA than those born earlier (Figure 4).  The 220 
reduction speeded up gradually after 1960, particularly for people aged 20-40 years, suggesting 221 
a potential aetiological change after 1960 that led to people being less likely to develop OA.  222 
In contrast, prevalence increased gradually by age but remained almost constant for people 223 
born after 1960.  The plot of distribution of incidence and prevalence across the age groups for 224 
different periods of birth is provided as supplementary material. (Supplementary Fig S7A & 225 
S7B) 226 
Discussion 227 
This study confirms a high burden of OA in the UK with a current (year 2017) prevalence of 228 
10.7% and incidence of 6.8 per 1000 person-years in people aged 20 and over. The prevalence 229 
of OA has increased at a rate of 1.4% per year since 1998, whereas the incidence is declining 230 
at a rate of -1.6% per year. Geographically, the prevalence and incidence of OA are not 231 
uniformly distributed. Scotland, Northern Ireland and West Midlands had higher prevalence 232 
compared to the rest of the country, whereas, the incidence was higher in East midlands and 233 
North-Eastern regions. 234 
The standardised incidence of OA in 2013 estimated from CPRD among people aged 45 years 235 
or more was 6.3 per 1000 person-years5. In another study, Yu et al reported the standardised 236 
rates of any OA incidence in 2010 as 8.6 per 1000 person-years among persons aged 15 years 237 
or more in a UK regional administrative database.25 According to the literature, the prevalence 238 
of OA among people aged 45 years and over varies between 20% to 35%.26,27 Our estimated 239 
prevalence among people aged 45 years or more using the entire CPRD database was nearly 240 
23%. Global burden of disease reports the prevalence of knee and hip was 7.3% and 241 
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musculoskeletal disease profile report from the National Health Services shows the prevalence 242 
in 2015-16 was nearly 12%.2,28 Comparing the incidence and prevalence across studies is very 243 
difficult because of the wide differences in study population, case definition, database quality 244 
and standardisation methods.4,27,29 Values similar to our prevalence estimates have been 245 
reported in the UK by Jordan et al30 using a database with better recording pattern, as the GPs 246 
from this region actively participate in musculoskeletal research.31 247 
These differences should not affect comparisons within the study such as, incidence by age and 248 
sex. The increase in incidence and prevalence of OA with age and in women supports existing 249 
epidemiological evidence.32 The sudden rise of both prevalence and incidence at age of 40 250 
years in women has been explained through biological sex hormone changes and also has been 251 
reported uniformly in previous studies.33,34 The incidence pattern with age also concurs  with 252 
previous studies in the UK and other countries.5,29 253 
In both sexes, the prevalence and incidence of ‘unspecified’ OA was high compared to reported 254 
joint-specific OA, a finding also reported by Yu et al.25 Such ‘unspecified’ reporting reflects 255 
the recording pattern in primary care, though whether the term ‘unspecified’ is a substitute to 256 
record multiple joint involvement, remains unclear. The higher burden of knee and hip OA in 257 
this study reflects consultation behaviour, for example a preference to seek advice for large 258 
joint rather than small joint problems. There is wide variation in reported prevalence of OA at 259 
individual joint sites. Again, this could indicate different methods of ascertainment, and 260 
whether diagnosis is purely clinical or based on presence of radiographic OA changes. Also 261 
the findings are likely to underrepresent true prevalence and incidence, as more than 12% of 262 
people with hip OA never consult GPs about their condition, even if it is symptomatic.13 263 
Trends of incidence and prevalence 264 
Surprisingly, there was an overall slow decline in incidence rates for any-OA since 1998. Yu 265 
et al found no change in trends of incidence physician-diagnosed OA for the period 1997-2013 266 
among people aged 45 years or more.5 One other population-based study in the US found no 267 
increase in trends of radiographic knee OA during the period 1974-1994 after adjusting for 268 
BMI change.35 The Joinpoint analysis reveals a slight rise in incidence from 2000-2004 269 
followed by a slow decline. We found significant increase in rate for knee and hip joint-specific 270 
incidence, but the ‘unspecified’ OA rate was declining, indicating possible improvement in 271 
clinical coding. Perhaps the increase in trend of ‘joint-pain’ after the year 2005 partially 272 
explains the gap (Supplementary Figure S6) if physicians became more prone to report 273 
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symptoms rather than a specific diagnosis. We observed a nearly 1.3 times increase in 274 
standardized prevalence of OA from 1998 to 2017, with an annual percentage increase of 1.4%. 275 
Globally, contribution of OA to the total prevalent cases has increased by 8.5% from 1990 to 276 
2017 and in the UK the prevalence has increased from 6.3% in 1990 to 7.7% in 2017.2 The 277 
increase in prevalence with the slow declining incidence rate is surprising. Especially, the 278 
increased prevalence trend could be because of the cumulative nature of the longitudinal 279 
database from electronic health records. CPRD is a dynamic database with people moving in 280 
and out of the database at any time point, which changes the eligible population every year. 281 
Also, we found the prevalence trend is becoming stable since 2008, which partially explains 282 
the effect of declining incidence. 283 
Age-period-cohort effects, length of data contribution and the participation of practices in the 284 
CPRD database influence the incidence estimates.14,30 Our age-period-cohort analysis shows a 285 
strong cohort effect in incidence among people born after the 1960s. It suggests  that people 286 
born after this period may  expose less to physically very demanding occupations such as coal-287 
mining, farming and certain heavy industrial work because of change in patterns of occupation 288 
in the UK since 1960s including the mining activities.36 We standardised for the length of data 289 
contribution period to eliminate the problem of prevalent cases for OA for robust incidence 290 
estimates. In contrast, prevalence remained almost unchanged in people born after 1960s 291 
(Figure 4), indicating the treatment of this condition may remain same.   292 
Geographical distribution   293 
 Scotland and the middle region of England and had higher incidence rates in 2014 compared 294 
to the rest of the UK.5 The reasons for regional variation could be differences in practice areas, 295 
socio-economic conditions, lifestyles and health seeking behaviours. Interestingly, higher 296 
prevalence in the Northern region largely matches the obesity distribution in the Northern 297 
region of the UK compared to the South.37 298 
Limitations of the study 299 
In addition to the highlighted caveats on coding of the diseases and data contribution, a few 300 
more limitations do exist. The case definition relied on the clinical diagnosis by the general 301 
practitioners without requiring demonstration of structural OA on imaging. However, 302 
concordance between symptoms and radiographic OA (the usual way to assess structural OA) 303 
is variable and often poor, depending on the joint site being assessed.38 Patient-centred 304 
outcomes rather than imaging changes are key determinants of disability and burden of disease, 305 
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and the National Institute for Health and Care Excellence (NICE) recommends that a purely 306 
clinical diagnosis is sufficient and that imaging should be reserved for specific situations such 307 
as atypical clinical features or rapid progression of symptoms.39 Coding of joint specific OA in 308 
a consultation database is always controversial. The index date reflects the date of allocation 309 
of Read codes for OA and does not reflect disease onset or the date of diagnosis. However, the 310 
date of allocation of a Read code for OA would be expected to be within a few months of the 311 
date of diagnosis.13 We did not perform a validation study for the OA definitions used in this 312 
study, therefore the results are open to misclassification bias. Caution must be taken when 313 
comparing the prevalence and incidence of this study with that reported in other studies.  314 
However, we believe this will not affect the internal validity, such as prevalence and incidence 315 
by age and gender,  and temporal trends of OA/joint pain in the past 20 years in the UK as they 316 
all were based on the same Read codes to define the disease. Furthermore, because our 317 
estimates are based on GP consultations for symptomatic regional joint pain, and not all people 318 
with symptomatic OA will consult their GP, these data may underestimate the true community 319 
prevalence and incidence of symptomatic OA. Unlike other chronic conditions, OA is not 320 
included in Quality and Outcome Framework (QOF) by the NHS in 2004. QOF is an 321 
incentivising program, which rewards GP practices in England for quality delivery of primary 322 
care including the diagnosis and recording of conditions. Therefore, the prevalence and 323 
incidence might have been underestimated. In addition, the exclusion criteria used in our study 324 
might have led to underestimation of the burden. Also, health care accessibility might influence 325 
the estimation. CPRD might have the duplication of people, because of the movement of 326 
patients from one practice area to other and being recorded with new unique identifier. 327 
However, we assume, the rate of migration might be similar in both OA group and ‘at-risk’ 328 
population. Even though, the method of standardising by length of data observation has been 329 
used previously for calculating trends using electronic health records, some residual 330 
confounding by length of data observation might still exist. Another limitation is the 331 
geographical presentation of the estimates, which needs cautious interpretation because of the 332 
non-uniform practices involved in the database. 333 
Conclusion  334 
One in 10 adults aged 20 years or more in the UK has GP-diagnosed OA and the knee was the 335 
leading site. The incidence of GP-diagnosed OA is declining, but the prevalence is rising 336 
slowly in the UK. A cohort effect was observed, that is, within the same age groups people 337 
born after 1960s had lower incidence than those born earlier. If it is a real change in trend or 338 
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change in recoding and reporting pattern needs to be studied. Also, further research is necessary 339 
to understand these temporal trends in OA.  340 
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Figure Caption:  482 
Fig. 1 Age specific incidence (A) and prevalence (B) of OA in 2017 483 
 484 
Shaded area represnts 95% confidence interval 485 
 486 
Fig. 2 Trends of standardized incidence (A) and prevalence (B) between 1998 and 2017 487 
488 
For Both: age-sex and length-of-data standardized rate; Men and Women: age and length of data standardized 489 
rate; Shaded area represents 95% confidence interval 490 
Trends are age-sex and length of data standardized using 2017 CPRD population 491 
  492 
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Fig. 3 Geographic variations in the incidence (A) and prevalence (B) of OA in the UK in 493 
2014 494 
A) Incidence           B) 495 
Prevalence 496 
 497 
 498 
Fig. 4 Age-period-cohort analysis of trend of OA (1997-2017) incidence (A) and prevalence 499 
(B) in the UK.   500 
A) Incidence          B) Prevalence 501 
 502 
 503 
 19 
 
Table 1. Crude and standardized incidence and prevalence of OA in the UK from 1997 to 2017 504 
 Incidence (per 1000 person-years) 
 
Prevalence (%) 
Year 
Person-
Year Cases Crude Incidence 
Age-sex 
standardized 
[95% CI] 
Age-sex-LOD 
standardized 
[95% CI] 
 
Eligible 
population Cases 
Crude 
Prevalence 
Age-sex 
Standardized 
[95% CI] 
Age-sex-LOD 
standardized 
[95% CI] 
1997 1321487 12296 9.30 [9.14-9.47] 9.17 [9.00-9.34]  
 
5711501 195362 3.42 [3.40-3.44] 6.15 [6.11-6.19]  
1998 1509159 14817 9.81 [9.66-9.97] 9.05 [8.89-9.20] 10.05 [7.43-12.67] 
 
5781677 215113 3.72 [3.70-3.74] 7.20 [7.16-7.24] 8.23 [8.06-8.40] 
1999 1831971 17216 9.39 [9.26-9.54] 8.87 [8.73-9.01] 10.69 [10.00-11.37] 
 
5848216 234835 4.01 [3.98-4.03] 7.41 [7.37-7.45] 8.47 [8.39-8.55] 
2000 2262732 20599 9.10 [8.98-9.22] 8.97 [8.84-9.11] 9.61 [9.31-9.92] 
 
5896329 255264 4.32 [4.30-4.35] 7.41 [7.37-7.44] 8.94 [8.88-9.00] 
2001 2534401 23615 9.31 [9.19-9.43] 9.20 [9.07-9.32] 9.36 [9.15-9.57] 
 
5900383 276091 4.77 [4.74-4.80] 7.87 [7.83-7.90] 9.08 [9.03-9.13] 
2002 2858237 26597 9.30 [9.19-9.41] 9.37 [9.25-9.49] 9.64 [9.44-9.84] 
 
5862771 296445 5.05 [5.02-5.08] 7.98 [7.95-8.01] 9.27 [9.22-9.32] 
2003 3046692 29358 9.63 [9.52-9.74] 9.63 [9.51-9.74] 10.00 [9.81-10.19] 
 
5788957 317611 5.48 [5.45-5.51] 8.19 [8.16-8.22] 9.47 [9.42-9.52] 
2004 3247175 32543 10.02 [9.91-10.13] 10.06 [9.95-10.17] 10.42 [10.23-10.61] 
 
5705620 339718 5.95 [5.92-5.98] 8.55 [8.52-8.58] 9.77 [9.73-9.82] 
2005 3317484 33093 9.97 [9.86-10.08] 10.15 [10.04-10.26] 10.33 [10.15-10.52] 
 
5615033 363534 6.47 [6.43-6.52] 9.06 [9.03-9.09] 10.21 [10.16-10.26] 
2006 3346598 30840 9.21 [9.11-9.31] 9.39 [9.29-9.50] 9.55 [9.37-9.72] 
 
5467107 378799 6.92 [6.90-6.94] 9.44 [9.42-9.47] 10.62 [10.57-10.66] 
2007 3374993 30236 8.95 [8.88-9.06] 9.15 [9.04-9.25] 9.49 [9.32-9.65] 
 
5294313 388708 7.34 [7.30-7.38] 9.73 [9.71-9.76] 10.64 [10.60-10.68] 
2008 3381824 30261 8.94 [8.84-9.05] 9.20 [9.10-9.30] 9.59 [9.44-9.74] 
 
5112496 398003 7.78 [7.74-7.82] 10.07 [10.04-10.10] 10.91 [10.87-10.95] 
2009 3362701 29387 8.73 [8.63-8.83] 8.99 [8.89-9.10] 9.36 [9.22-9.50] 
 
4924529 405402 8.23 [8.20-8.26] 10.35 [10.32-10.38] 10.91 [10.88-10.95] 
2010 3314620 27133 8.18 [8.09-8.28] 8.42 [8.32-8.52] 8.74 [8.62-8.87] 
 
4689058 403343 8.60 [8.56-8.64] 10.54 [10.51-10.57] 10.93 [10.90-10.96] 
2011 3235505 26100 8.06 [7.96-8.16] 8.30 [8.20-8.40] 8.48 [8.36-8.59] 
 
4421201 398434 9.01 [8.96-9.06] 10.69 [10.66-10.72] 10.94 [10.91-10.97] 
2012 3196392 24727 7.73 [7.64-7.83] 7.95 [7.85-8.05] 8.10 [7.90-8.30] 
 
4165371 391691 9.40 [9.36-9.44] 10.76 [10.73-10.79] 10.87 [10.84-10.90] 
2013 3030317 23409 7.72 [7.62-7.82] 7.87 [7.77-7.97] 7.94 [7.84-8.05] 
 
3812788 374298 9.82 [9.78-9.86] 10.87 [10.84-10.90] 10.90 [10.87-10.93] 
2014 2758065 21113 7.65 [7.55-7.75] 7.74 [7.64-7.85] 7.75 [7.65-7.86] 
 
3314992 337168 10.17 [10.14-10.20] 10.96 [10.93-10.99] 10.95 [10.92-10.98] 
2015 2360852 17690 7.49 [7.38-7.60] 7.52 [7.41-7.63] 7.51 [7.40-7.62] 
 
2761702 290020 10.50 [10.47-10.53] 10.94 [10.90-10.97] 10.93 [10.90-10.96] 
2016 1889587 13540 7.16 [7.04-7.28] 7.18 [7.06-7.30] 7.17 [7.05-7.29] 
 
2100061 223948 10.66 [10.63-10.69] 10.96 [10.93-11.00] 10.95 [10.92-10.99] 
2017 1495497 10146 6.78 [6.67-6.93] 6.78 [6.67-6.93] 6.78 [6.67-6.93] 
 
1690618 181464 10.77 [10.72-10.82] 10.77 [10.72-10.82] 10.77 [10.72-10.82] 
 505 
 506 
 507 
 508 
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 509 
 Hip  Knee  Wrist/Hand  Ankle/Foot  Unspecified 
 Men Women  Men Women  Men Women  Men Women  Men Women 
1998 0.95 [0.92-0.98] 1.24 [1.21-1.27]  2.19 [1.15-2.24] 2.51 [2.48-2.54]  0.30 [0.27-0.33] 0.60 [0.56-0.64]  0.28 [0.24-0.32] 0.41 [0.38-0.44]  4.18 [4.15-4.21] 6.27 [6.24-6.30] 
1999 0.86 [0.83-0.89] 1.18 [1.15-1.21]  2.14 [2.11-2.15] 2.56 [2.52-2.60]  0.28 [0.24-0.31] 0.62[0.59-0.65]  0.31 [0.29-0.33] 0.43 [0.40-0.47]  4.48 [4.45-4.51] 6.75 [6.71-6.79] 
2000 0.90 [0.87-0.93] 1.25 [1.22-1.29]  2.11 [2.06-2.16] 2.63 [2.58-2.68]  0.27 [0.26-0.29] 0.61 [0.58-0.63]  0.27 [0.25-0.29] 0.35 [0.33-0.36]  4.82 [4.75-4.89] 7.51 [7.43-7.59] 
2001 0.92 [0.89-0.95] 1.28 [1.25-1.31]  2.13 [2.09-2.18] 2.67 [2.63-2.72]  0.27 [0.26-0.29] 0.63 [0.60-0.65]  0.27 [0.25-0.29] 0.34 [0.32-0.36]  4.92 [4.86-4.98] 7.64 [7.57-7.72] 
2002 0.93 [0.91-0.96] 1.30 [1.27-1.33]  2.14 [2.10-2.18] 2.69 [2.65-2.73]  0.27 [0.25-0.28] 0.61 [0.59-0.63]  0.27 [0.25-0.28] 0.33 [0.32-0.35]  5.08 [5.02-5.14] 7.92 [7.85-7.99] 
2003 0.96 [0.93-0.98] 1.33 [1.30-1.36]  2.21 [2.18-2.25] 2.76 [2.72-2.80]  0.27 [0.26-0.29] 0.62 [0.60-0.64]  0.27 [0.26-0.28] 0.33 [0.31-0.34]  5.17 [5.12-5.23] 8.08 [8.02-8.15] 
2004 0.98 [0.95-1.01] 1.36 [1.33-1.39]  2.26 [2.22-2.30] 2.81 [2.77-2.85]  0.28 [0.26-0.29] 0.64 [0.62-0.66]  0.27 [0.26-0.29] 0.34 [0.32-0.35]  5.37 [5.31-5.43] 8.46 [8.40-8.53] 
2005 1.04 [1.01-1.06] 1.43 [1.40-1.46]  2.32 [2.28-2.36] 2.89 [2.85-2.93]  0.28 [0.27-0.30] 0.66 [0.64-0.68]  0.28 [0.26-0.29] 0.34 [0.33-0.35]  5.70 [5.65-5.76] 8.97 [8.90-9.03] 
2006 1.05 [1.03-1.08] 1.48 [1.45-1.51]  2.39 [2.35-2.42] 2.98 [2.94-3.01]  0.29 [0.28-0.31] 0.68 [0.67-0.70]  0.28 [0.27-0.30] 0.35 [0.34-0.36]  5.97 [5.92-6.02] 9.36 [9.30-9.42] 
2007 1.05 [1.03-1.07] 1.48 [1.45-1.50]  2.36 [2.33-2.39] 2.96 [2.92-2.99]  0.28 [0.27-0.30] 0.67 [0.65-0.68]  0.27 [0.26-0.29] 0.33 [0.32-0.34]  6.03 [5.98-6.08] 9.47 [9.41-9.53] 
2008 1.10 [1.08-1.12] 1.55 [1.52-1.57]  2.46 [2.43-2.49] 3.09 [3.06-3.13]  0.30 [0.28-0.31] 0.69 [0.68-0.71]  0.29 [0.28-0.30] 0.35 [0.33-0.36]  6.13 [6.09-6.18] 9.62 [9.57-9.67] 
2009 1.09 [1.07-1.11] 1.55 [1.53-1.57]  2.42 [2.40-2.45] 3.10 [3.07-3.13]  0.29 [0.28-0.30] 0.71 [0.69-0.72]  0.28 [0.28-0.29] 0.34 [0.33-0.35]  6.11 [6.07-6.15] 9.68 [9.64-9.73] 
2010 1.10 [1.08-1.12] 1.56 [1.54-1.58]  2.44[2.41-2.47] 3.13 [3.11-3.16]  0.29 [0.28-0.30] 0.71 [0.70-0.72]  0.29 [0.28-0.30] 0.34 [0.33-0.35]  6.12 [6.08-6.16] 9.66 [9.62-9.71] 
2011 1.12 [1.11-1.14] 1.59 [1.57-1.61]  2.50 [2.48-2.52] 3.22 [3.19-3.24]  0.30 [0.29-0.31] 0.73 [0.71-0.74]  0.29 [0.28-0.30] 0.35 [0.34-0.36]  6.03 [5.99-6.06] 9.58 [9.54-9.62] 
2012 1.11 [1.09-1.12] 1.57 [1.55-1.59]  2.46 [2.43-2.48] 3.16 [3.13-3.19]  0.29 [0.29-0.30] 0.71 [0.70-0.73]  0.28 [0.27-0.29] 0.33 [0.32-0.33]  5.99 [5.96-6.03] 9.57 [9.52-9.61] 
2013 1.12 [1.11-1.14] 1.58 [1.57-1.60]  2.49 [2.46-2.51] 3.20 [3.17-3.23  0.29 [0.28-0.30] 0.72 [0.70-0.73]  0.28 [0.27-0.29] 0.33 [0.32-0.34]  5.97 [5.93-6.00] 9.56 [9.52-9.60] 
2014 1.16 [1.14-1.18] 1.63 [1.61-1.65]  2.56 [2.53-2.58] 3.29 [3.26-3.31]  0.30 [0.30-0.31] 0.74 [0.73-0.76]  0.29 [0.28-0.30] 0.34 [0.33-0.35]  5.92 [5.88-5.95] 9.50 [9.46-9.54] 
2015 1.20 [1.18-1.22] 1.68 [1.66-1.70]  2.60 [2.58-2.63] 3.36 [3.33-3.39]  0.32 [0.31-0.32] 0.77 [0.76-0.79]  0.30 [0.29-0.31] 0.35 [0.34-0.36]  5.79 [5.76-5.83] 9.38 [9.34-9.42] 
2016 1.19 [1.17-1.21] 1.65 [1.63-1.68]  2.55 [2.53-2.58] 3.26 [3.23-3.29]  0.30 [0.29-0.31] 0.74 [0.73-0.76]  0.28 [0.27-0.29] 0.33 [0.32-0.34]  5.91 [5.87-5.95] 9.49 [9.44-9.54] 
2017 1.20 [1.18-1.22] 1.68 [1.65-1.70]  2.51 [2.48-2.54] 3.23 [3.19-3.26]  0.29 [0.28-0.31] 0.74 [0.72-0.75]  0.27 [0.26-0.28] 0.32 [0.31-0.34]  5.77 [5.73-5.82] 9.35 [9.30-9.41] 
AAPC  1.5 [0.9 to 1.9]* 1.8 [1.5 to 2.1]*  0.9 [0.4 to 1.4]* 1.3 [1.0 to 1.7]*  0.2 [-0.4 to 0.9] 1.3 [1.1 to 1.5]  0.1 [-0.2 to 0.4] -1.2 [-2.0 to -0.3]*  1.7 [1.3 to 2.1]* 2.2 [1.9 to 2.5]* 
AAPC: Average annual percentage change; CI- Confidence interval; Age and length of data standardized using 2017 CPRD population; *P-value <0.05 510 
 511 
 512 
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 514 
 515 
 Hip  Knee  Wrist/Hand  Ankle/Foot  Unspecified 
 Men Women  Men Women  Men Women  Men Women  Men Women 
1998 0.86 [0.74-0.98] 1.20[1.12-1.27]  1.69 [1.26-2.02] 2.00 [1.89-2.11]  0.44 [0.34-0.54] 0.89 [0.80-0.98]  0.25 [0.19-0.28] 0.18 [0.02-0.99]  6.72 [3.73-9.71] 10.76 [6.91-14.62] 
1999 0.74 [0.48-0.99] 1.08 [0.79-1.38]  1.70 [1.31-2.09] 2.12 [1.70-2.53]  0.35 [0.29-0.41] 0.85 [0.77-0.93]  0.29 [0.12-0.45] 0.15 [0.041-0.26]  7.22 [6.42-8.03] 12.12 [11.11-13.12] 
2000 0.71 [0.60-0.83] 1.15 [1.01-1.30]  1.94 [1.74-2.13] 2.19 [1.98-2.40]  0.34 [0.27-0.42] 0.73 [0.67-0.79]  0.23 [0.16-0.29] 0.22 [0.16-0.29]  6.29 [5.94-6.65] 9.93 [9.49-10.37] 
2001 0.96 [0.86-1.06] 1.24 [1.13-1.34]  2.00 [1.87-2.14] 2.77 [2.61-2.92]  0.32 [0.22-0.42] 0.61 [0.55-0.67]  0.15 [0.11-0.19] 0.23 [0.19-0.28]  5.64 [5.41-5.88] 9.02 [8.73-9.31] 
2002 1.03 [0.93-1.12] 1.38 [1.28-1.48]  2.12 [1.98-2.25] 2.70 [2.55-2.84]  0.36 [0.30-0.42] 0.78 [0.71-0.85]  0.17 [0.13-0.21] 0.24 [0.19-0.28]  5.77 [5.55-5.99] 9.22 [8.95-9.49] 
2003 0.98 [0.89-1.07] 1.32 [1.23-1.41]  2.26 [2.13-2.39] 2.95 [2.81-3.09]  0.36 [0.30-0.42] 0.74 [0.68-0.80]  0.19 [0.15-0.23] 0.21 [0.17-0.24]  5.91 [5.7-6.12] 9.72 [9.46-9.98] 
2004 1.12 [1.04-1.21] 1.47 [1.37-1.57]  2.44 [2.31-2.57] 3.04 [2.90-3.19]  0.40 [0.32-0.49] 0.86 [0.80-0.92]  0.18 [0.15-0.22] 0.24 [0.20-0.28]  6.02 [5.82-6.23] 10.33 [10.07-10.59] 
2005 1.00 [0.92-1.08] 1.44 [1.34-1.53]  2.21 [2.09-2.33] 3.00 [2.86-3.14]  0.40 [0.31-0.49] 0.94 [0.89-0.99]  0.16 [0.12-0.20] 0.25 [0.21-0.29]  6.18 [5.98-6.38] 10.42 [10.15-10.69] 
2006 0.98 [0.90-1.06] 1.32 [1.24-1.41]  2.34 [2.22-2.47] 2.99 [2.85-3.12]  0.43 [0.39-0.46] 0.89 [0.85-0.94]  0.19 [0.15-0.24] 0.22 [0.18-0.26]  5.53 [5.33-5.73] 9.31 [9.07-9.55] 
2007 1.02 [0.96-1.08] 1.41 [1.33-1.49]  2.30 [2.19-2.42] 3.01 [2.89-3.14]  0.41 [0.37-0.44] 0.92 [0.87-0.97]  0.24 [0.20-0.28] 0.24 [0.21-0.28]  5.43 [5.33-5.53] 8.96 [8.74-9.18] 
2008 1.05 [1.00-1.10] 1.39 [1.31-1.47]  2.36 [2.25-2.46] 3.01 [2.90-3.13]  0.41 [0.38-0.45] 0.94 [0.88-0.97]  0.21 [0.17-0.25] 0.27 [0.23-0.30]  5.42 [5.33-5.51] 9.14 [8.93-9.35] 
2009 1.0 [0.93-1.07] 1.43 [1.36-1.51]  2.42 [2.32-2.52] 3.14 [3.03-3.25]  0.44 [0.40-0.47] 1.06 [1.01-1.11]  0.24 [0.20-0.28] 0.28 [0.24-0.31]  5.41 [5.30-5.52] 8.68 [8.49-8.87] 
2010 0.96 [0.90-1.02] 1.33 [1.27-1.40]  2.31 [2.22-2.40] 3.02 [2.92-3.12]  0.49 [0.46-0.54] 1.08 [1.02-1.13]  0.21 [0.18-0.24] 0.22 [0.19-0.25]  4.93 [4.85-5.02] 8.11 [7.94-8.28] 
2011 0.97 [0.91-1.03] 1.39 [1.32-1.45]  2.24 [2.16-2.32] 2.98 [2.88-3.07]  0.48 [0.45-0.52] 1.09 [1.04-1.15]  0.22 [0.19-0.25] 0.23 [0.21-0.26]  4.62 [4.56-4.68] 7.71 [7.55-7.86] 
2012 0.92 [0.87-0.97] 1.31 [1.25-1.38]  2.17 [2.09-2.25] 2.90 [2.81-2.99]  0.47 [0.43-0.51] 1.07 [1.01-1.12]  0.19 [0.16-0.22] 0.22 [0.20-0.25]  4.37 [4.29-4.45] 7.44 [7.29-7.6] 
2013 0.94 [0.89-0.99] 1.30 [1.25-1.36]  2.04 [1.97-2.12] 2.80 [2.71-2.88]  0.46 [0.42-0.50] 1.07 [1.01-1.12]  0.18 [0.15-0.21] 0.20 [0.18-0.22]  4.33 [4.20-4.46] 7.26 [7.12-7.40] 
2014 0.98 [0.91-1.05] 1.37 [1.31-1.43]  2.17 [2.09-2.25] 2.87 [2.78-2.96]  0.46 [0.42-0.50] 1.04 [0.97-1.10]  0.20 [0.14-0.26] 0.23 [0.20-0.25]  4.02 [3.92-4.12] 6.83 [6.7-6.97] 
2015 0.97 [0.91-1.04] 1.31 [1.24-1.37]  2.19 [2.10-2.27] 2.75 [2.66-2.84]  0.49 [0.45-0.54] 1.09 [1.02-1.16]  0.19 [0.13-0.25] 0.22 [0.19-0.24]  3.94 [3.83-4.05] 6.65 [6.51-6.80] 
2016 0.96 [0.90-1.02] 1.37 [1.30-1.44]  1.98 [1.89-2.06] 2.51 [2.42-2.61]  0.50 [0.45-0.55] 1.04 [0.97-1.11]  0.19 [0.13-0.25] 0.21 [0.19-0.24]  3.77 [3.63-3.90] 6.44 [6.27-6.60] 
2017 0.93 [0.86-0.99] 1.37 [1.29-1.45]  1.93 [1.83-2.02] 2.63 [2.52-2.74]  0.42 [0.37-0.47] 1.04 [0.96-1.12]  0.17 [0.14-0.20] 0.21 [0.18-0.25]  3.71 [3.57-3.84] 6.02 [5.84-6.19] 
AAPC 1.2 [0.0 to 2.3]* 1.0 [0.2 to 1.7]*  1.1 [0.3 to 1.8]* 1.6 [0.8 to 2.3]*  0.4 [-1.6 to 2.3] 0.8 [-0.5 to 2.0]  -2.5 [-5.1 to 0.1] 3.6 [1.0 to 6.2]*  -3.2 [-4.0 to -2.4]* -3.3 [-5.4 to -1.2]* 
 516 
 517 
Age-sex and length of data contribution (LOD) standardization was done using 2017 CPRD population as standard population. For 1997, LOD standardisation was not calculated because of absence of data for >=10 518 
years. (See Supplementary Figure S1, S2) 519 
IR: Incidence Rate; CI: Confidence Interval; AAPC: Annual Average Percentage Change; *P-value  520 
